BMY Bristol Myers Squibb PEG ratio, current and historical analysis

Bristol Myers Squibb is trading with a PEG ratio of 0.46, based on Jun 22, 2026 data. Dividing the 15.32 PE ratio by the 33.2% earnings growth rate yields this valuation metric. Relative to the 0.2 average from the previous four quarters, the PEG ratio has soared by 133%.

Historically, Bristol Myers Squibb shows a PEG ratio averaging 0.28 across the past ten years. At 0.46, today's PE to growth ratio sits 64% above its historical average. The ten years high occurred in the Mar 2023 quarter at 0.92, reflecting maximum valuation relative to growth. The minimum was hit in the Jun 2019 quarter at 0.01, indicating optimal value relative to growth during that period.

Measured against past performance, BMY's PEG ratio is higher than its 3, 5 and 10-year averages.

PEG comparison

With a PEG of 0.46, BMY is below the Healthcare sector, the industry and its peers average. Compared to its Healthcare sector average of 0.55, Bristol Myers Squibb's PEG is 16% lower.

Compared to its peers, BMY's PEG ratio is under NVS's and AZN's but above LLY's. Bristol Myers Squibb's PEG ratio of 0.46 is below the peer average of 1.04.